Form4insider filings, from the source

SEC Form 4/A · accession 0001209191-18-054521

Ultragenyx Pharmaceutical Inc. · RARE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Karah Herdman Parschauer
Officer — EVP and General Counsel
Period of report
Aug 21, 2018
Accepted (ET)
Oct 9, 2018 · 4:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001515673

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockAug 21, 2018M5,000$54.50A19,181D
Common StockF1,F2Aug 21, 2018S5,000$78.53D14,181D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Right to Buy)F3$54.50Aug 21, 2018M5,000D—Jun 20, 2026Common Stock5,00055,000D

Explanation of responses

Remarks

This amendment is filed to report the exercise of 5000 previously awarded stock options that was part of the same day sale reported on August 21, 2018 and to correct the direct holdings reported therein. No other changes were made to the information reported on the original Form 4 filed on August 21, 2018.